Fortrea Clinical Development Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 17-07-2024
- Paid Up Capital ₹ 0.24 M
as on 17-07-2024
- Company Age 22 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -8.49%
(FY 2023)
- Profit 55.49%
(FY 2023)
- Ebitda -42.84%
(FY 2023)
- Net Worth 18.64%
(FY 2023)
- Total Assets 13.81%
(FY 2023)
About Fortrea Clinical Development
The Corporate was formerly known as Omnicare Clinical Research India Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.24 M, as per Ministry of Corporate Affairs (MCA) records.
Rishi Sharma, David Cooper, and Rangarajan Narasimhan serve as directors at the Company.
- CIN/LLPIN
U73100KA2002PTC031038
- Company No.
031038
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Sep 2002
- Date of AGM
26 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bengaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Fortrea Clinical Development?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rishi Sharma  | Director | 11-Sep-2023 | Current |
David Cooper  | Director | 30-Jun-2023 | Current |
| Rangarajan Narasimhan | Director | 24-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Fortrea Clinical Development.
Fortrea Clinical Development Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.49% decrease. The company also saw a substantial improvement in profitability, with a 55.49% increase in profit. The company's net worth Soared by an impressive increase of 18.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fortrea Clinical Development?
In 2023, Fortrea Clinical Development had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fortrea Scientific Private LimitedActive 17 years 8 monthsRishi Sharma, David Cooper and 1 more are mutual person
Fortrea Development India Private LimitedActive 17 years 5 monthsRishi Sharma, David Cooper and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fortrea Clinical Development?
Fortrea Clinical Development has a workforce of 219 employees as of Mar 24, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fortrea Clinical Development, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fortrea Clinical Development's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
